KITE-222

N/A

Report date: 2024/06/24 15:53:20

Base Information

Drug NameKITE-222

Drug Alias NameKITE-222

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionC-Type lectin domain family 12 member A modulators

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFrance

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKite Pharma

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKite Pharma

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A